Pharma Industry

Laurus Labs: Laurus Labs strikes gold by moving up the value chain. But there’s a steeper climb ahead.


Satyanarayana Chava, founder & CEO, Laurus Lab; image credits: Laurus Labs


Laurus Labs has been a strong player in active pharmaceutical ingredients for antiretrovirals. It has now gone ahead and built a sizeable finished-products business. But given that growth in antiretrovirals could plateau soon and scaling up in markets like the US is a challenge, there will be questions over maintaining the momentum in the formulations business.

In December 2016, a relatively young company from Hyderabad, making active pharmaceutical ingredients (APIs) mostly for HIV drugs, made a decent debut on the stock exchanges at a 14% premium on its issue price. Today, it is a chartbuster. Laurus Labs has come into the limelight, with its share price and earnings hitting new highs. There is increasing interest among investors in this company, which posted a whopping 1,047% growth in net profit

  • SAVE

Sign in to read the full article

You’ve got this Prime Story as a Free Gift

Already a Member?

Why ?

  • Sharp Insight-rich, Indepth stories across 20+ sectors

  • Access the exclusive Economic Times stories, Editorial and Expert opinion

  • Clean experience with
    Minimal Ads

  • Comment & Engage with ET Prime community

  • Exclusive invites to Virtual Events with Industry Leaders

  • A trusted team of Journalists & Analysts who can best filter signal from noise


Source link